Ganulameran - Pfizer/Shanghai Fosun Pharmaceutical
Alternative Names: BNT-162b3Latest Information Update: 28 Apr 2024
At a glance
- Originator BioNTech
- Developer BioNTech; Pfizer; Shanghai Fosun Pharmaceutical
- Class COVID-19 vaccines; RNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II COVID 2019 infections
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (IM, Injection)
- 05 May 2023 Arbutus Biopharma files patent infringement lawsuit against Pfizer and BioNTech seeking compensation for use of unlicensed patented technologies in COVID-19 mRNA-LNP vaccines
- 07 Feb 2022 BioNTech completes a phase I/II trial in COVID-2019 infections (Prevention) in Germany (IM) (NCT04537949)